<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653546</url>
  </required_header>
  <id_info>
    <org_study_id>AZD3759-003</org_study_id>
    <nct_id>NCT03653546</nct_id>
  </id_info>
  <brief_title>First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases</brief_title>
  <acronym>BM</acronym>
  <official_title>A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Biopharma (Jiangsu) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Biopharma (Jiangsu) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Hypothesis The first-line treatment with single agent AZD3759 results in superior
      Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor
      Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced Non-Small Cell Lung
      Cancer (NSCLC) with Central Nervous System (CNS) metastasis

      Secondary Hypothesis The safety profile of AZD3759 is comparable to EGFR TKI first-line
      treatment in patients with advanced NSCLC with CNS metastasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and
      safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients
      with advanced NSCLC with CNS metastases.

      Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced
      NSCLC and documented intracranial disease will be enrolled.

      Primary Objective:

      The primary objective of this study is to determine if administration of single agent AZD3759
      compared to Standard of Care (SoC) EGFR-TKI as first-line therapy results in a significant
      increase in Progression Free Survival (PFS) in the study patient population by Blinded
      Independent Central Radiological(BICR) review.

      Secondary Objectives:

      Key secondary objective for this study is to determine if AZD3759 vs. SoC EGFR TKI
      administration demonstrates additional benefit in terms of safety, Objective Response Rate
      (ORR), Disease Control Rate (DCR), Duration of Response (DoR), and overall PFS using modified
      RECIST 1.1 criteria by investigator assessment.

      Additional secondary objectives include assessment of Health Related Quality of Life (HRQoL),
      neurological function, and Overall Survival (OS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">October 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by Blinded Independent Central Radiological</measure>
    <time_frame>36 months</time_frame>
    <description>To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assess by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Investigator assessment of PFS using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS (iPFS) assessed by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS (iPFS) assessed by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial PFS (ePFS) assessed by investigator</measure>
    <time_frame>36 months</time_frame>
    <description>Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial PFS (ePFS) assessed by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR） assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall ORR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall ORR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall DCR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall DCR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall DoR assessed by investigator using RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Overall DoR assessed by investigator using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>ORR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>DCR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR for Intracranial lesions assessed by investigator using RANO-BM</measure>
    <time_frame>36 months</time_frame>
    <description>DoR for Intracranial lesions assessed by investigator using RANO-BM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).</measure>
    <time_frame>36 months</time_frame>
    <description>The 30-items questionnaire measures cancer patients' functioning and symptoms. The scale range of EORTC QLQ-C30 is 30-126. Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).</measure>
    <time_frame>36 months</time_frame>
    <description>The 20-items questionnaire was used among brain cancer patients. The scale range of EORTC BN20 is 20-80. Lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)</measure>
    <time_frame>36 months</time_frame>
    <description>Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological function improvement rate assessed by RANO-BM criteria</measure>
    <time_frame>36 months</time_frame>
    <description>Neurological function improvement rate assessed by RANO-BM criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood Pressure assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Systolic and Diastolic Blood Pressure assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Pulse rate to assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature assessed during the study period.</measure>
    <time_frame>36 months</time_frame>
    <description>Body temperature assessed during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS assess by BICR</measure>
    <time_frame>36 months</time_frame>
    <description>Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR Gene Mutation</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>AZD3759 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3759 group will receive a 200 mg twice daily dose of AZD3759</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3759</intervention_name>
    <description>Advanced Non-Small Cell Lung Cancer (NSCLC) with CNS metastases.</description>
    <arm_group_label>AZD3759 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>SoC EGFRTKI Erlotinib 150 mg PO Q.D</description>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>SoC EGFRTKI Gefitinib 250 mg PO Q.D</description>
    <arm_group_label>Erlotinib or Gefitinib Group</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Properly completed patient informed consent

          2. Male or female aged at least 18 years

          3. Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR
             mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by
             local or central laboratory testing on tumour tissue or plasma utilizing a validated
             methodology which has been approved by the regulatory authority.

          4. No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are
             considered first line treatment for advanced NSCLC.

          5. All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with
             Magnetic Resonance Imaging (MRI) documented CNS metastases that include brain
             metastases (BM). BM + patients with co- existent leptomeningeal involvement are
             eligible for the study.

          6. Eligible patients are not candidates for definitive surgical resection or radiation of
             all lesions in the opinion of the treating physician.

          7. All patients must be stable without any systemic (oral or parenteral) corticosteroid
             or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled
             non-absorbable and topical corticosteroid use are permitted as indicated.

          8. Patients may have prior placement of a properly functioning CNS shunt or Ommaya
             reservoir.

          9. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no
             deterioration over the previous 2 weeks.

         10. Women of child-bearing potential and male subjects shall agree to take medically
             acceptable contraception measures while on study treatment and for 3 months following
             completion of study treatment. All women of child-bearing potential must have a
             negative blood pregnancy test at screening.

         11. (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS
             lesion, which was not previously irradiated, that can be accurately measured at
             baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate
             repeated measurements. Measurable extracranial disease is not required. (b) For
             Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion,
             which has not been previously irradiated, within the screening period that can be
             accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes
             which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated
             measurement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Ju Ahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qing Zhou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Ge, M.D.</last_name>
    <phone>+86 (0)21-63862197</phone>
    <email>john.ge@alphabiopharma.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Lu, M.D.</last_name>
    <phone>+86(0)21-63862186</phone>
    <email>yang.lu@alphabiopharma.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China site 0104</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyin Pan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0108</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Zhuang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0128</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingxun Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0101</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0132</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yubiao Guo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0110</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0109</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyong Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0131</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guojun Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0111</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0112</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0114</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanping Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0142</name>
      <address>
        <city>Yichang</city>
        <state>Hubei</state>
        <zip>443003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinhua Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0113</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0122</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0118</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Feng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0124</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhixiang Zhuang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0125</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosheng Hang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0126</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longzhen Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0119</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buhai Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0116</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0117</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuwei Cui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0127</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0123</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligang Xing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0121</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0138</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guohua Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0140</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0135</name>
      <address>
        <city>Shenyang</city>
        <state>Shenyang</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunpeng Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0141</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0129</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaofeng Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0136</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0137</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Fan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0115</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>311100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0102</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0133</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjun Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0105</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0130</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0106</name>
      <address>
        <city>Chongqing</city>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0120</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0134</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ge Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0103</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0107</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China site 0139</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diansheng Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Site 0203</name>
      <address>
        <city>Chungbuk</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0210</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0209</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0206</name>
      <address>
        <city>Gyeongsang</city>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0205</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea Site 0202</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0212</name>
      <address>
        <city>Seoul</city>
        <zip>05368</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea Site 0201</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0204</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0211</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0207</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea site 0208</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Singapore site 0301</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taiwan site 0403</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taiwan site 0404</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taiwan site 0401</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taiwan site 0402</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Barajas RF Jr, Cha S. Imaging diagnosis of brain metastasis. Prog Neurol Surg. 2012;25:55-73. doi: 10.1159/000331174. Epub 2012 Jan 6. Review.</citation>
    <PMID>22236668</PMID>
  </reference>
  <reference>
    <citation>Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007 Mar 15;13(6):1663-74. Review.</citation>
    <PMID>17363519</PMID>
  </reference>
  <reference>
    <citation>Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468.</citation>
    <PMID>18172267</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Nervous System Metastases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>EGFR</keyword>
  <keyword>Exon 19Del</keyword>
  <keyword>L858R</keyword>
  <keyword>Lung Neoplasm</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03653546/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

